

# Patrizia Burra

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6602382/publications.pdf>

Version: 2024-02-01

467  
papers

18,054  
citations

14655

66  
h-index

20961

115  
g-index

479  
all docs

479  
docs citations

479  
times ranked

14604  
citing authors

#	ARTICLE	IF	CITATIONS
1	EASL Clinical Practice Guidelines: Liver transplantation. <i>Journal of Hepatology</i> , 2016, 64, 433-485.	3.7	744
2	EASL Clinical Practical Guidelines: Management of Alcoholic Liver Disease. <i>Journal of Hepatology</i> , 2012, 57, 399-420.	3.7	602
3	Transcatheter Arterial Chemoembolization (TACE) in Hepatocellular Carcinoma (HCC): The Role of Angiogenesis and Invasiveness. <i>American Journal of Gastroenterology</i> , 2008, 103, 914-921.	0.4	429
4	A significant proportion of myofibroblasts are of bone marrow origin in human liver fibrosis. <i>Gastroenterology</i> , 2004, 126, 955-963.	1.3	405
5	Iron storage, lipid peroxidation and glutathione turnover in chronic anti-HCV positive hepatitis. <i>Journal of Hepatology</i> , 1995, 22, 449-456.	3.7	365
6	European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. <i>Gastroenterology</i> , 1999, 117, 619-625.	1.3	345
7	Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma. <i>Transplantation</i> , 2016, 100, 116-125.	1.0	339
8	Liver Transplantation for the Treatment of Moderately or Well-Differentiated Hepatocellular Carcinoma. <i>Annals of Surgery</i> , 2004, 239, 150-159.	4.2	289
9	Liver Transplantation for Alcoholic Liver Disease in Europe: A Study from the ELTR (European Liver) Tj ETQq1 1 0.784314 rgBT /Overlo 4.7 286	4.7	286
10	Prospective evaluation of anticoagulation and transjugular intrahepatic portosystemic shunt for the management of portal vein thrombosis in cirrhosis. <i>Liver International</i> , 2012, 32, 919-927.	3.9	284
11	Report of the Paris consensus meeting on expanded criteria donors in liver transplantation. <i>Liver Transplantation</i> , 2008, 14, 1694-1707.	2.4	257
12	The EASL "Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. <i>Lancet, The</i> , 2022, 399, 61-116.	13.7	257
13	Liver transplantation for acute liver failure in Europe: Outcomes over 20years from the ELTR database. <i>Journal of Hepatology</i> , 2012, 57, 288-296.	3.7	236
14	Practical Recommendations for Long-term Management of Modifiable Risks in Kidney and Liver Transplant Recipients. <i>Transplantation</i> , 2017, 101, S1-S56.	1.0	217
15	β-blockers protect against spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis. <i>Liver International</i> , 2009, 29, 1189-1193.	3.9	207
16	Prophylaxis and treatment of hepatitis B in immunocompromised patients. <i>Digestive and Liver Disease</i> , 2007, 39, 397-408.	0.9	197
17	The empirical antibiotic treatment of nosocomial spontaneous bacterial peritonitis: Results of a randomized, controlled clinical trial. <i>Hepatology</i> , 2016, 63, 1299-1309.	7.3	186
18	Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: A multicentre study. <i>Journal of Hepatology</i> , 2015, 62, 617-624.	3.7	184

#	ARTICLE	IF	CITATIONS
19	Management of Nonneoplastic Portal Vein Thrombosis in the Setting of Liver Transplantation. <i>Transplantation</i> , 2012, 94, 1145-1153.	1.0	183
20	Improved clinical outcomes for liver transplant recipients using cyclosporine monitoring based on 2-hr post-dose levels (C2)1. <i>Transplantation</i> , 2002, 73, 953-959.	1.0	178
21	International Liver Transplantation Society Consensus Statement on Immunosuppression in Liver Transplant Recipients. <i>Transplantation</i> , 2018, 102, 727-743.	1.0	178
22	Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC. <i>Journal of Hepatology</i> , 2017, 66, 552-559.	3.7	166
23	A Multistep, Consensus-Based Approach to Organ Allocation in Liver Transplantation: Toward a "Blended Principle Model" American Journal of Transplantation, 2015, 15, 2552-2561.	4.7	164
24	Neurologic complications after solid organ transplantation. <i>Transplant International</i> , 2009, 22, 269-278.	1.6	163
25	The critical issue of hepatocellular carcinoma prognostic classification: which is the best tool available?. <i>Journal of Hepatology</i> , 2004, 40, 124-131.	3.7	161
26	New insights into the coagulopathy of liver disease and liver transplantation. <i>World Journal of Gastroenterology</i> , 2006, 12, 7725.	3.3	151
27	A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma. <i>BMC Cancer</i> , 2010, 10, 190.	2.6	146
28	Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: a systematic review. <i>Transplant International</i> , 2014, 27, 1039-1049.	1.6	145
29	Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantation. <i>Journal of Hepatology</i> , 2001, 34, 888-894.	3.7	144
30	CD105(+) cells from Wharton's jelly show in vitro and in vivo myogenic differentiative potential. <i>International Journal of Molecular Medicine</i> , 2006, 18, 1089-96.	4.0	143
31	Adherence in liver transplant recipients. <i>Liver Transplantation</i> , 2011, 17, 760-770.	2.4	138
32	Barcelona Clinic Liver Cancer staging and transplant survival benefit for patients with hepatocellular carcinoma: a multicentre, cohort study. <i>Lancet Oncology</i> , The, 2011, 12, 654-662.	10.7	135
33	Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: A prospective population study. <i>Journal of Hepatology</i> , 2018, 69, 345-352.	3.7	128
34	Risk of cancer following immunosuppression in organ transplant recipients and in HIV-positive individuals in southern Europe. <i>European Journal of Cancer</i> , 2007, 43, 2117-2123.	2.8	127
35	Liver transplantation for HCV cirrhosis: Improved survival in recent years and increased severity of recurrent disease in female recipients: Results of a long term retrospective study. <i>Liver Transplantation</i> , 2007, 13, 733-740.	2.4	124
36	The impact of liver disease and medical complications on quality of life and psychological distress before and after liver transplantation. <i>Journal of Hepatology</i> , 2000, 33, 609-615.	3.7	122

#	ARTICLE	IF	CITATIONS
37	Recent advances in alcohol-related liver disease (ALD): summary of a Gut round table meeting. Gut, 2020, 69, 764-780.	12.1	112
38	Intention-to-Treat Analysis of Liver Transplantation in Selected, Aggressively Treated HCC Patients Exceeding the Milan Criteria. American Journal of Transplantation, 2007, 7, 972-981.	4.7	111
39	Influence of steroids on HCV recurrence after liver transplantation: A prospective study. Journal of Hepatology, 2007, 47, 793-798.	3.7	104
40	Quality of life following organ transplantation. Transplant International, 2007, 20, 397-409.	1.6	103
41	Liver transplantation for HBV-related cirrhosis in Europe: An ELTR study on evolution and outcomes. Journal of Hepatology, 2013, 58, 287-296.	3.7	99
42	Endothelial activation and circulating vascular adhesion molecules in alcoholic liver disease. Hepatology, 1994, 19, 588-594.	7.3	96
43	A randomized study on Peg-interferon alfa-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C. Journal of Hepatology, 2007, 46, 1009-1017.	3.7	96
44	NAFLD and liver transplantation: Disease burden, current management and future challenges. JHEP Reports, 2020, 2, 100192.	4.9	96
45	Liver transplantation for patients with acute-on-chronic liver failure (ACLF) in Europe: Results of the ELITA/EF-CLIF collaborative study (ECLIS). Journal of Hepatology, 2021, 75, 610-622.	3.7	96
46	Nonalcoholic fatty liver disease and liver transplantation - Where do we stand?. World Journal of Gastroenterology, 2018, 24, 1491-1506.	3.3	95
47	Detection of circulating intercellular adhesion molecule-1 in chronic liver diseases. Hepatology, 1992, 16, 810-814.	7.3	94
48	Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: A cost-benefit analysis while awaiting data on sorafenib safety. Hepatology, 2010, 51, 165-173.	7.3	93
49	Histological features after liver transplantation in alcoholic cirrhotics. Journal of Hepatology, 2001, 34, 716-722.	3.7	90
50	Double-Blind Comparison of Hepatitis C Histological Recurrence Rate in HCV+ Liver Transplant Recipients Given Basiliximab+Steroids or Basiliximab+Placebo, in addition to Cyclosporine and Azathioprine. Transplantation, 2004, 78, 1488-1495.	1.0	90
51	A method for establishing allocation equity among patients with and without hepatocellular carcinoma on a common liver transplant waiting list. Journal of Hepatology, 2014, 60, 290-297.	3.7	89
52	Balancing Donor and Recipient Risk Factors in Liver Transplantation: The Value of D-MELD With Particular Reference to HCV Recipients. American Journal of Transplantation, 2011, 11, 2724-2736.	4.7	86
53	mTOR Inhibition Is Most Beneficial After Liver Transplantation for Hepatocellular Carcinoma in Patients With Active Tumors. Annals of Surgery, 2020, 272, 855-862.	4.2	85
54	Mortality in liver transplant recipients with portal vein thrombosis - an updated meta-analysis. Transplant International, 2018, 31, 1318-1329.	1.6	84

#	ARTICLE	IF	CITATIONS
55	Veno occlusive disease: Update on clinical management. <i>World Journal of Gastroenterology</i> , 2007, 13, 3918.	3.3	79
56	Long-Term Follow-Up and Outcome of Liver Transplantation From Anti-Hepatitis C Virus-Positive Donors: A European Multicentric Case-Control Study. <i>Transplantation</i> , 2011, 91, 1265-1272.	1.0	79
57	Management of infections pre- and post-liver transplantation: Report of an AISF consensus conference. <i>Journal of Hepatology</i> , 2014, 60, 1075-1089.	3.7	77
58	Hepatic encephalopathy 2018: A clinical practice guideline by the Italian Association for the Study of the Liver (AISF). <i>Digestive and Liver Disease</i> , 2019, 51, 190-205.	0.9	77
59	Factors influencing renal function after liver transplantation. Results from the MOST, an international observational study. <i>Digestive and Liver Disease</i> , 2009, 41, 350-356.	0.9	76
60	International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Candidates. <i>Transplantation</i> , 2017, 101, 945-955.	1.0	76
61	Liver abnormalities and endocrine diseases. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2013, 27, 553-563.	2.4	75
62	CD105(+) cells from Wharton's jelly show in vitro and in vivo myogenic differentiative potential. <i>International Journal of Molecular Medicine</i> , 2006, 18, 1089.	4.0	73
63	Changing Attitude to Organ Donation and Transplantation in University Students During the Years of Medical School in Italy. <i>Transplantation Proceedings</i> , 2005, 37, 547-550.	0.6	71
64	Allocation of liver grafts worldwide " Is there a best system?. <i>Journal of Hepatology</i> , 2019, 71, 707-718.	3.7	71
65	Liver Match, a prospective observational cohort study on liver transplantation in Italy: Study design and current practice of donor-recipient matching. <i>Digestive and Liver Disease</i> , 2011, 43, 155-164.	0.9	69
66	Neuropsychological alterations in hepatitis C infection: The role of inflammation. <i>World Journal of Gastroenterology</i> , 2011, 17, 3369.	3.3	69
67	Nonadherent Behaviors After Solid Organ Transplantation. <i>Transplantation Proceedings</i> , 2011, 43, 318-323.	0.6	68
68	A prospective multicentre study of the epidemiology and outcomes of bloodstream infection in cirrhotic patients. <i>Clinical Microbiology and Infection</i> , 2018, 24, 546.e1-546.e8.	6.0	67
69	Development and Validation of a Comprehensive Model to Estimate Early Allograft Failure Among Patients Requiring Early Liver Re transplant. <i>JAMA Surgery</i> , 2020, 155, e204095.	4.3	67
70	Response to Therapy as a Criterion for Awarding Priority to Patients With Hepatocellular Carcinoma Awaiting Liver Transplantation. <i>Annals of Surgical Oncology</i> , 2010, 17, 2290-2302.	1.5	66
71	Acute alcoholic hepatitis, end stage alcoholic liver disease and liver transplantation: An Italian position statement. <i>World Journal of Gastroenterology</i> , 2014, 20, 14642.	3.3	66
72	Thromboelastometry hypercoagulable profiles and portal vein thrombosis in cirrhotic patients with hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2017, 49, 440-445.	0.9	66

#	ARTICLE	IF	CITATIONS
73	Histology predicts cirrhotic evolution of post transplant hepatitis C. <i>Gut</i> , 2002, 50, 697-700.	12.1	65
74	Liver Transplantation for Alcoholic Liver Disease. <i>Transplantation</i> , 2016, 100, 981-987.	1.0	65
75	Bone Metabolism and Gonad Function in Male Patients Undergoing Liver Transplantation: A Two-Year Longitudinal Study. <i>Osteoporosis International</i> , 2001, 12, 749-754.	3.1	64
76	Management of Recurrent and De Novo NAFLD/NASH After Liver Transplantation. <i>Transplantation</i> , 2019, 103, 57-67.	1.0	64
77	A randomized study comparing ligation with propranolol for primary prophylaxis of variceal bleeding in candidates for liver transplantation. <i>Liver Transplantation</i> , 2007, 13, 1272-1278.	2.4	63
78	Current challenges and future directions for liver transplantation. <i>Liver International</i> , 2017, 37, 317-327.	3.9	62
79	Neoplastic disease after liver transplantation: Focus on de novo neoplasms. <i>World Journal of Gastroenterology</i> , 2015, 21, 8753.	3.3	62
80	Comparison of de novo tumours after liver transplantation with incidence rates from Italian cancer registries. <i>Digestive and Liver Disease</i> , 2010, 42, 55-60.	0.9	59
81	Systemic administration of a novel human umbilical cord mesenchymal stem cells population accelerates the resolution of acute liver injury. <i>BMC Gastroenterology</i> , 2012, 12, 88.	2.0	58
82	A prediction model for successful anticoagulation in cirrhotic portal vein thrombosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 34-42.	1.6	58
83	Clinical impact of sexual dimorphism in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). <i>Liver International</i> , 2021, 41, 1713-1733.	3.9	58
84	Biopsy-proven acute cellular rejection as an efficacy endpoint of randomized trials in liver transplantation: a systematic review and critical appraisal. <i>Transplant International</i> , 2016, 29, 961-973.	1.6	57
85	Markers of acute rejection and graft acceptance in liver transplantation. <i>World Journal of Gastroenterology</i> , 2015, 21, 1061.	3.3	57
86	Practice guidelines for the treatment of hepatitis C: Recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting. <i>Digestive and Liver Disease</i> , 2010, 42, 81-91.	0.9	56
87	Anticoagulation for the treatment of thrombotic complications in patients with cirrhosis. <i>Liver International</i> , 2012, 32, 1465-1476.	3.9	55
88	Influence of Age and Gender Before and After Liver Transplantation. <i>Liver Transplantation</i> , 2013, 19, 122-134.	2.4	55
89	De Novo Autoimmune Hepatitis after Liver Transplantation. <i>Seminars in Liver Disease</i> , 2011, 31, 071-081.	3.6	53
90	A Prospective Policy Development to Increase Split-Liver Transplantation for 2 Adult Recipients. <i>Annals of Surgery</i> , 2014, 259, 157-165.	4.2	53

#	ARTICLE	IF	CITATIONS
91	Response to Terlipressin and Albumin Is Associated With Improved Liver Transplant Outcomes in Patients With Hepatorenal Syndrome. <i>Hepatology</i> , 2021, 73, 1909-1919.	7.3	53
92	Is the intercellular adhesion molecule-1/leukocyte function associated antigen 1 pathway of leukocyte adhesion involved in the tissue damage of alcoholic hepatitis?. <i>Gut</i> , 1992, 33, 268-271.	12.1	52
93	Homologous acellular matrix (HAM): a new support for hepatocyte culture. <i>Journal of Hepatology</i> , 2002, 36, 218-219.	3.7	51
94	Occurrence of post-transplant lymphoproliferative disorders among over thousand adult recipients: any role for hepatitis C infection?. <i>European Journal of Gastroenterology and Hepatology</i> , 2006, 18, 1065-1070.	1.6	51
95	Validation of the BCLC Prognostic System in Surgical Hepatocellular Cancer Patients. <i>Transplantation Proceedings</i> , 2009, 41, 1260-1263.	0.6	51
96	Summary of candidate selection and expanded criteria for liver transplantation for hepatocellular carcinoma: A review and consensus statement. <i>Liver Transplantation</i> , 2011, 17, S81-S89.	2.4	51
97	Cancer-Associated Thrombosis in Cirrhotic Patients with Hepatocellular Carcinoma. <i>Cancers</i> , 2018, 10, 450.	3.7	51
98	Kaposi's Sarcoma in Transplant and HIV-infected Patients: An Epidemiologic Study in Italy and France. <i>Transplantation</i> , 2005, 80, 1699-1704.	1.0	50
99	Liver transplantation in alcoholic patients. <i>Transplant International</i> , 2005, 18, 491-498.	1.6	50
100	Hepatitis C. <i>Seminars in Liver Disease</i> , 2009, 29, 053-065.	3.6	50
101	Bone metabolism in orthotopic liver transplantation: A prospective study. <i>Liver Transplantation</i> , 1998, 4, 311-319.	1.8	49
102	The impact of liver disease and medical complications on quality of life and psychological distress before and after liver transplantation. <i>Journal of Hepatology</i> , 2000, 33, 609-615.	3.7	49
103	Hepatitis C virus: from oxygen free radicals to hepatocellular carcinoma. <i>Journal of Viral Hepatitis</i> , 2007, 14, 821-829.	2.0	49
104	Liver transplantation for unresectable hepatocellular carcinoma in normal livers. <i>Journal of Hepatology</i> , 2012, 57, 297-305.	3.7	49
105	Umbilical cord mesenchymal stem cells modulate dextran sulfate sodium induced acute colitis in immunodeficient mice. <i>Stem Cell Research and Therapy</i> , 2015, 6, 79.	5.5	49
106	Aprotinin efficacy on intraoperative bleeding and transfusion requirements in orthotopic liver transplantation. <i>Transfusion</i> , 1994, 34, 507-511.	1.6	48
107	Sexual Dysfunction in Chronic Liver Disease: Is Liver Transplantation an Effective Cure?. <i>Transplantation</i> , 2010, 89, 1425-1429.	1.0	48
108	De Novo Tumors Are a Major Cause of Late Mortality After Orthotopic Liver Transplantation. <i>Transplantation Proceedings</i> , 2009, 41, 1303-1305.	0.6	46

#	ARTICLE	IF	CITATIONS
109	Dropout rate from the liver transplant waiting list because of hepatocellular carcinoma progression in hepatitis C virus-infected patients treated with direct-acting antivirals. <i>Liver Transplantation</i> , 2017, 23, 1103-1112.	2.4	46
110	HBV and HCV infections in heart transplant recipients. <i>Journal of Heart and Lung Transplantation</i> , 2001, 20, 718-724.	0.6	45
111	Torque Teno virus: any pathological role in liver transplanted patients?. <i>Transplant International</i> , 2008, 21, 972-979.	1.6	45
112	Hepatitis B-core antibody positive donors in liver transplantation and their impact on graft survival: Evidence from the Liver Match cohort study. <i>Journal of Hepatology</i> , 2013, 58, 715-723.	3.7	44
113	International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Recipients. <i>Transplantation</i> , 2017, 101, 956-967.	1.0	44
114	Increased platelet aggregation in patients with decompensated cirrhosis indicates higher risk of further decompensation and death. <i>Journal of Hepatology</i> , 2022, 77, 660-669.	3.7	43
115	The survival benefit of liver transplantation in hepatocellular carcinoma patients. <i>Digestive and Liver Disease</i> , 2010, 42, 642-649.	0.9	42
116	Immunosuppression and Cancer: A Comparison of Risks in Recipients of Organ Transplants and in HIV-Positive Individuals. <i>Transplantation Proceedings</i> , 2006, 38, 3533-3535.	0.6	41
117	Different neurological outcome of liver transplantation for Wilson's disease in two homozygotic twins. <i>Clinical Neurology and Neurosurgery</i> , 2007, 109, 71-75.	1.4	41
118	Donor livers with steatosis are safe to use in hepatitis C virus-positive recipients. <i>Liver Transplantation</i> , 2009, 15, 619-628.	2.4	41
119	Anticoagulation for portal vein thrombosis in cirrhotic patients should be always considered. <i>Internal and Emergency Medicine</i> , 2009, 4, 161-162.	2.0	41
120	Recurrence of hepatocellular carcinoma after direct acting antiviral treatment for hepatitis C virus infection: Literature review and risk analysis. <i>Digestive and Liver Disease</i> , 2018, 50, 1105-1114.	0.9	41
121	Endothelial Damage of the Portal Vein is Associated with Heparin-Like Effect in Advanced Stages of Cirrhosis. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1173-1181.	3.4	41
122	Posttransplant Management of Recipients Undergoing Liver Transplantation for Hepatocellular Carcinoma. Working Group Report From the ILTS Transplant Oncology Consensus Conference. <i>Transplantation</i> , 2020, 104, 1143-1149.	1.0	41
123	Regional cerebral blood flow changes in patients with cirrhosis assessed with <sup>99m</sup> Tc-HM-PAO single-photon emission computed tomography: effect of liver transplantation. <i>Journal of Hepatology</i> , 1998, 29, 78-84.	3.7	40
124	Management of infections in cirrhotic patients: Report of a Consensus Conference. <i>Digestive and Liver Disease</i> , 2014, 46, 204-212.	0.9	40
125	White Paper of Italian Gastroenterology: Delivery of services for digestive diseases in Italy: Weaknesses and strengths. <i>Digestive and Liver Disease</i> , 2014, 46, 579-589.	0.9	40
126	Risk Factors for Central Pontine and Extrapontine Myelinolysis After Liver Transplantation. <i>Transplantation</i> , 2015, 99, 1257-1264.	1.0	40



#	ARTICLE	IF	CITATIONS
127	Managing severe alcoholic hepatitis complicated by renal failure. QJM - Monthly Journal of the Association of Physicians, 1993, 86, 649-656.	0.5	39
128	Killer cell immunoglobulin-like receptor genotype and killer cell immunoglobulin-like receptor-human leukocyte antigen C ligand compatibility affect the severity of hepatitis C virus recurrence after liver transplantation. Liver Transplantation, 2009, 15, 390-399.	2.4	39
129	Reversal of hypercoagulability in patients with <sc>HCV</sc>-related cirrhosis after treatment with direct-acting antivirals. Liver International, 2018, 38, 2210-2218.	3.9	39
130	Including Relative Adrenal Insufficiency in Definition and Classification of Acute-on-Chronic Liver Failure. Clinical Gastroenterology and Hepatology, 2020, 18, 1188-1196.e3.	4.4	39
131	11 beta-Hydroxysteroid dehydrogenase deficiency and glucocorticoid status in patients with alcoholic and non-alcoholic chronic liver disease. Journal of Clinical Endocrinology and Metabolism, 1993, 76, 748-751.	3.6	39
132	Primary liver transplantation for autoimmune hepatitis: A comparative analysis of the European Liver Transplant Registry. Liver Transplantation, 2010, 16, NA-NA.	2.4	38
133	Hepatocellular Carcinoma in Chronic Viral Hepatitis: Where Do We Stand?. International Journal of Molecular Sciences, 2022, 23, 500.	4.1	37
134	Understanding of and attitudes to xenotransplantation: a survey among Italian university students. Xenotransplantation, 2004, 11, 133-140.	2.8	36
135	Risk of Kaposi Sarcoma after Solid-Organ Transplantation: Multicenter Study in 4767 Recipients in Italy, 1970-2006. Transplantation Proceedings, 2009, 41, 1227-1230.	0.6	36
136	Liver transplantation for viral hepatitis in 2015. World Journal of Gastroenterology, 2016, 22, 1570.	3.3	36
137	Therapeutic approaches for portal biliopathy: A systematic review. World Journal of Gastroenterology, 2016, 22, 9909.	3.3	35
138	The Health Care Transition of Youth With Liver Disease Into the Adult Health System. Journal of Pediatric Gastroenterology and Nutrition, 2018, 66, 976-990.	1.8	35
139	Ethical review of COVID-19 vaccination requirements for transplant center staff and patients. American Journal of Transplantation, 2022, 22, 371-380.	4.7	35
140	Skin Cancer and Other Cutaneous Disorders in Liver Transplant Recipients. Acta Dermato-Venereologica, 2012, 92, 411-415.	1.3	34
141	Fifteen years and 382 extended right grafts from in situ split livers in a multicenter study: Are these still extended criteria liver grafts?. Liver Transplantation, 2015, 21, 500-511.	2.4	33
142	Clinical significance of alpha-fetoprotein mRNA in blood of patients with hepatocellular carcinoma. Clinica Chimica Acta, 2004, 347, 129-138.	1.1	32
143	The Concept of Quality of Life in Organ Transplantation. Transplantation Proceedings, 2007, 39, 2285-2287.	0.6	32
144	AISF position paper on liver disease and pregnancy. Digestive and Liver Disease, 2016, 48, 120-137.	0.9	32

#	ARTICLE	IF	CITATIONS
145	Sexual dysfunction after liver transplantation. <i>Liver Transplantation</i> , 2009, 15, S50-S56.	2.4	31
146	Hepatitis C virus related cirrhosis decreased as indication to liver transplantation since the introduction of direct-acting antivirals: A single-center study. <i>World Journal of Gastroenterology</i> , 2018, 24, 4403-4411.	3.3	31
147	Effect of penicillamine and zinc on iron metabolism in Wilson's disease. <i>Scandinavian Journal of Gastroenterology</i> , 2007, 42, 1495-1500.	1.5	30
148	Long-Term Evaluation of Cognitive Function and Cerebral Metabolism in Liver Transplanted Patients. <i>Transplantation Proceedings</i> , 2009, 41, 1295-1296.	0.6	30
149	Limitations of current liver donor allocation systems and the impact of newer indications for liver transplantation. <i>Journal of Hepatology</i> , 2021, 75, S178-S190.	3.7	30
150	Female gender in the setting of liver transplantation. <i>World Journal of Transplantation</i> , 2014, 4, 229.	1.6	30
151	HLA-DRB1 Donor-Recipient Mismatch Affects the Outcome of Hepatitis C Disease Recurrence After Liver Transplantation. <i>Gastroenterology</i> , 2006, 130, 695-702.	1.3	29
152	The adolescent and liver transplantation. <i>Journal of Hepatology</i> , 2012, 56, 714-722.	3.7	29
153	Lack of agreement for defining "clinical suspicion of rejection" in liver transplantation: a model to select candidates for liver biopsy. <i>Transplant International</i> , 2015, 28, 455-464.	1.6	29
154	Long-term care of transplant recipients. <i>Current Opinion in Organ Transplantation</i> , 2018, 23, 187-195.	1.6	29
155	Extended Infusion of $\beta$ -Lactams for Bloodstream Infection in Patients With Liver Cirrhosis: An Observational Multicenter Study. <i>Clinical Infectious Diseases</i> , 2019, 69, 1731-1739.	5.8	29
156	Coagulopathy is not predictive of bleeding in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure. <i>Liver International</i> , 2021, 41, 2455-2466.	3.9	29
157	Liver transplantation for severe alcoholic hepatitis: A multicenter Italian study. <i>American Journal of Transplantation</i> , 2022, 22, 1191-1200.	4.7	29
158	Partial hepatectomy as first-line treatment for patients with hepatocellular carcinoma. <i>Journal of Surgical Oncology</i> , 2007, 95, 213-220.	1.7	28
159	Risk Factors in Liver Retransplantation: A Single-Center Experience. <i>Transplantation Proceedings</i> , 2011, 43, 1110-1113.	0.6	28
160	Age and equity in liver transplantation: An organ allocation model. <i>Liver Transplantation</i> , 2015, 21, 1241-1249.	2.4	28
161	Survival after the diagnosis of <i>de novo</i> malignancy in liver transplant recipients. <i>International Journal of Cancer</i> , 2019, 144, 232-239.	5.1	28
162	Sorafenib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplantation?. <i>Transplantation Proceedings</i> , 2012, 44, 1989-1991.	0.6	27

#	ARTICLE	IF	CITATIONS
163	Platelets and Hepatocellular Cancer: Bridging the Bench to the Clinics. <i>Cancers</i> , 2019, 11, 1568.	3.7	27
164	Microwave Thermal Ablation for Hepatocarcinoma: Six Liver Transplantation Cases. <i>Transplantation Proceedings</i> , 2011, 43, 1091-1094.	0.6	26
165	<a href="http://www.D-MELD.com">http://www.D-MELD.com</a> , the Italian survival calculator to optimize donor to recipient matching and to identify the unsustainable matches in liver transplantation. <i>Transplant International</i> , 2012, 25, 294-301.	1.6	26
166	Physical Activity in Solid Organ Transplant Recipients: Organizational Aspects and Preliminary Results of the Italian Project. <i>Transplantation Proceedings</i> , 2014, 46, 2345-2349.	0.6	26
167	Restaging Patients With Hepatocellular Carcinoma Before Additional Treatment Decisions: A Multicenter Cohort Study. <i>Hepatology</i> , 2018, 68, 1232-1244.	7.3	26
168	Liver Transplantation for Alcoholic Liver Disease and Hepatocellular Carcinoma. <i>Cancers</i> , 2018, 10, 46.	3.7	26
169	Invasive fungal infection before and after liver transplantation. <i>World Journal of Gastroenterology</i> , 2020, 26, 7485-7496.	3.3	26
170	Balancing Utility and Need by Means of Donor-to-Recipient Matching: A Challenging Problem. <i>American Journal of Transplantation</i> , 2013, 13, 522-523.	4.7	25
171	Neuropsychological and Neurophysiological Evaluation in Cirrhotic Patients With Minimal Hepatic Encephalopathy Undergoing Liver Transplantation. <i>Transplantation Proceedings</i> , 2005, 37, 1104-1107.	0.6	24
172	Understanding of and attitudes to organ donation and transplantation: a survey among Italian university students. <i>Clinical Transplantation</i> , 2006, 20, 307-312.	1.6	24
173	Microvascular Autonomic Dysfunction May Justify False-Positive Stress Myocardial Perfusion Imaging in Patients With Liver Cirrhosis Undergoing Liver Transplantation. <i>Transplantation Proceedings</i> , 2008, 40, 1916-1917.	0.6	24
174	Tips for portal vein thrombosis (pvt) in cirrhosis: Not only unblocking a pipe. <i>Journal of Hepatology</i> , 2011, 55, 945-946.	3.7	24
175	Liver transplantation in Italy: current status. <i>Digestive and Liver Disease</i> , 2000, 32, 249-256.	0.9	23
176	The transjugular route: The key hole to the liver world. <i>Digestive and Liver Disease</i> , 2007, 39, 105-116.	0.9	23
177	Hepatitis C virus infection in end-stage renal disease and kidney transplantation. <i>Transplant International</i> , 2014, 27, 877-891.	1.6	23
178	Common issues in the management of patients in the waiting list and after liver transplantation. <i>Digestive and Liver Disease</i> , 2017, 49, 241-253.	0.9	23
179	Organ Preservation in Liver Transplantation. <i>Seminars in Liver Disease</i> , 2018, 38, 260-269.	3.6	23
180	The Current Management of Hepatorenal Syndrome—Acute Kidney Injury in the United States and the Potential of Terlipressin. <i>Liver Transplantation</i> , 2021, 27, 1191-1202.	2.4	23

#	ARTICLE	IF	CITATIONS
181	Severity of alcoholic liver disease and markers of thyroid and steroid status. <i>Postgraduate Medical Journal</i> , 1992, 68, 804-810.	1.8	22
182	Should donors and recipients be matched in liver transplantation?. <i>Journal of Hepatology</i> , 2006, 45, 488-494.	3.7	22
183	Strengthening acceptance for xenotransplantation: the case of attraction effect. <i>Xenotransplantation</i> , 2008, 15, 159-163.	2.8	22
184	The Impact of Hepatitis C and Biliary Complications on Patient and Graft Survival Following Liver Transplantation. <i>American Journal of Transplantation</i> , 2009, 9, 1398-1405.	4.7	22
185	Influence of donor and recipient gender on liver transplantation outcomes in Europe. <i>Liver International</i> , 2020, 40, 1961-1971.	3.9	22
186	Development of a Risk Prediction Model for Carbapenem-resistant <i>Enterobacteriaceae</i> Infection After Liver Transplantation: A Multinational Cohort Study. <i>Clinical Infectious Diseases</i> , 2021, 73, e955-e966.	5.8	22
187	Does liver-disease aetiology have a role in cerebral blood-flow alterations in liver cirrhosis?. <i>European Journal of Gastroenterology and Hepatology</i> , 2004, 16, 885-890.	1.6	21
188	Management of Hepatitis C Virus Infection Recurrence After Liver Transplantation: An Overview. <i>Transplantation Proceedings</i> , 2011, 43, 291-295.	0.6	21
189	Polyclonal and monoclonal B lymphocytes response in HCV-infected patients treated with direct-acting antiviral agents. <i>Journal of Viral Hepatitis</i> , 2017, 24, 1168-1176.	2.0	21
190	Risk of virus and non-virus related malignancies following immunosuppression in a cohort of liver transplant recipients. Italy, 1985-2014. <i>International Journal of Cancer</i> , 2018, 143, 1588-1594.	5.1	21
191	Sex-dependent differences in inflammatory responses during liver regeneration in a murine model of acute liver injury. <i>Clinical Science</i> , 2018, 132, 255-272.	4.3	21
192	Machine learning in liver transplantation: a tool for some unsolved questions?. <i>Transplant International</i> , 2021, 34, 398-411.	1.6	21
193	Influence of Hepatocellular Carcinoma on Platelet Aggregation in Cirrhosis. <i>Cancers</i> , 2021, 13, 1150.	3.7	21
194	Risk factors and outcomes associated with recurrent autoimmune hepatitis following liver transplantation. <i>Journal of Hepatology</i> , 2022, 77, 84-97.	3.7	21
195	Combined liver-kidney transplantation in a 15-year-old boy with alpha1-antitrypsin deficiency. <i>Journal of Hepatology</i> , 2002, 36, 565-568.	3.7	20
196	Antiviral Therapy for Hepatitis C Virus Recurrence Following Liver Transplantation: Long-Term Results From a Single Center Experience. <i>Transplantation Proceedings</i> , 2006, 38, 1127-1130.	0.6	20
197	Progression of Hepatocellular Carcinoma Before Liver Transplantation: Dropout or Liver Transplantation?. <i>Transplantation Proceedings</i> , 2009, 41, 1264-1267.	0.6	20
198	Long-term quality of life for transplant recipients. <i>Liver Transplantation</i> , 2013, 19, S40-S43.	2.4	20

#	ARTICLE	IF	CITATIONS
199	A rare combination of type 3 autoimmune polyendocrine syndrome (APS-3) or multiple autoimmune syndrome (MAS-3). <i>Autoimmunity Highlights</i> , 2014, 5, 27-31.	3.9	20
200	AISF position paper on liver transplantation and pregnancy. <i>Digestive and Liver Disease</i> , 2016, 48, 860-868.	0.9	20
201	Hepatitis C virus eradication with direct-acting antiviral improves insulin resistance. <i>Journal of Viral Hepatitis</i> , 2020, 27, 188-194.	2.0	20
202	New Indications for Liver Transplantation. <i>Journal of Clinical Medicine</i> , 2021, 10, 3867.	2.4	20
203	<sup>18</sup> F-fluorodeoxyglucose positron emission tomography study of brain metabolism in cirrhosis: effect of liver transplantation. <i>Transplantation Proceedings</i> , 1999, 31, 418-420.	0.6	19
204	Macroenzymes: too often overlooked. <i>Journal of Hepatology</i> , 2003, 38, 119.	3.7	19
205	Differential timing of oxidative DNA damage and telomere shortening in hepatitis C and B virus-related liver carcinogenesis. <i>Translational Research</i> , 2016, 168, 122-133.	5.0	19
206	Specific issues concerning the management of patients on the waiting list and after liver transplantation. <i>Liver International</i> , 2018, 38, 1338-1362.	3.9	19
207	The Lancet's EASL Commission on liver diseases in Europe: overcoming unmet needs, stigma, and inequities. <i>Lancet, The</i> , 2018, 392, 621-622.	13.7	19
208	New Perspectives in Liver Transplantation: From Regeneration to Bioengineering. <i>Bioengineering</i> , 2019, 6, 81.	3.5	19
209	Is osteoporosis a peculiar association with primary biliary cirrhosis?. <i>World Journal of Gastroenterology</i> , 2005, 11, 5347.	3.3	19
210	Protocol liver biopsies in long-term management of patients transplanted for hepatitis B-related liver disease. <i>World Journal of Gastroenterology</i> , 2006, 12, 1706.	3.3	19
211	COVID-19 and liver disease: where are we now?. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 277-278.	17.8	19
212	Zinc, iron, and peroxidation in liver tissue. <i>Biological Trace Element Research</i> , 1995, 47, 193-199.	3.5	18
213	Adjuvant chemotherapy for transplanted hepatocellular carcinoma patients: impact on survival or HCV recurrence timing. <i>Transplantation Proceedings</i> , 2003, 35, 2991-2994.	0.6	18
214	Estimation of the Harm to the Waiting List as a Crucial Factor in the Selection of Patients With Hepatocellular Carcinoma for Liver Transplantation. <i>Transplantation Proceedings</i> , 2010, 42, 1194-1196.	0.6	18
215	Primary biliary cirrhosis: Symptomatic treatment. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1991, 6, 570-573.	2.8	17
216	Understanding of and attitude to xenotransplantation among Italian university students: impact of a 3-yr university course. <i>Xenotransplantation</i> , 2006, 13, 264-271.	2.8	17

#	ARTICLE	IF	CITATIONS
217	Development and validation of a questionnaire evaluating the impact of hepatitis B immune globulin prophylaxis on the quality of life of liver transplant recipients. <i>Liver Transplantation</i> , 2012, 18, 332-339.	2.4	17
218	Who Fares Worse After Liver Transplantation? Impact of Donor and Recipient Variables on Outcome. <i>Transplantation</i> , 2013, 95, 1528-1534.	1.0	17
219	A new prognostic model to predict dropout from the waiting list in cirrhotic candidates for liver transplantation with MELD score <math>\leq 18</math>. <i>Liver International</i> , 2015, 35, 184-191.	3.9	17
220	Recurrence of Hepatitis B Infection in Liver Transplant Patients Receiving Long-Term Hepatitis B Immunoglobulin Prophylaxis. <i>Annals of Transplantation</i> , 2018, 23, 789-801.	0.9	17
221	Therapeutic application of stem cells in gastroenterology: An up-date. <i>World Journal of Gastroenterology</i> , 2011, 17, 3870.	3.3	17
222	Haemostatic alterations in patients with cirrhosis and hepatocellular carcinoma: laboratory evidence and clinical implications. <i>Liver International</i> , 2022, 42, 1229-1240.	3.9	17
223	Acellular liver matrix improves the survival and functions of isolated rat hepatocytes cultured in vitro. <i>International Journal of Molecular Medicine</i> , 2004, 14, 511-5.	4.0	17
224	Global hemostatic profiling in patients with decompensated cirrhosis and bacterial infections. <i>JHEP Reports</i> , 2022, 4, 100493.	4.9	17
225	More Pronounced Hypercoagulable State and Hypofibrinolysis in Patients With Cirrhosis With Versus Without HCC. <i>Hepatology Communications</i> , 2021, 5, 1987-2000.	4.3	16
226	Growth hormone/insulin-like growth factor 1 axis recovery after liver transplantation: A preliminary prospective study. <i>Liver Transplantation</i> , 2004, 10, 692-698.	2.4	15
227	ABO Blood Group-Related Waiting List Disparities in Liver Transplant Candidates: Effect of the MELD Adoption. <i>Transplantation</i> , 2008, 85, 844-849.	1.0	15
228	Bax Inhibitor-1 down-regulation in the progression of chronic liver diseases. <i>BMC Gastroenterology</i> , 2010, 10, 35.	2.0	15
229	Liver transplantation for hepatocellular carcinoma in clinical practice. <i>European Journal of Gastroenterology and Hepatology</i> , 2012, 24, 195-202.	1.6	15
230	Trends in liver transplantation 2011. <i>Journal of Hepatology</i> , 2012, 56, S101-S111.	3.7	15
231	Early HCV viral kinetics under DAAs may optimize duration of therapy in patients with compensated cirrhosis. <i>Liver International</i> , 2019, 39, 826-834.	3.9	15
232	Management of Hepatocellular Carcinoma Recurrence after Liver Transplantation. <i>Cancers</i> , 2021, 13, 4882.	3.7	15
233	Comparison of Fondaparinux and Low-Molecular-Weight Heparin in the Treatment of Portal Vein Thrombosis in Cirrhosis. <i>American Journal of Medicine</i> , 2021, 134, 1278-1285.e2.	1.5	15
234	Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO). <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2022, 32, 1-16.	2.6	15

#	ARTICLE	IF	CITATIONS
235	Donor-Model for End-Stage Liver Disease and Donor-Recipient Matching in Liver Transplantation. <i>Transplantation Proceedings</i> , 2011, 43, 974-976.	0.6	14
236	Biodegradable Biliary Stents for Percutaneous Treatment of Post-liver Transplantation Refractory Benign Biliary Anastomotic Strictures. <i>CardioVascular and Interventional Radiology</i> , 2020, 43, 749-755.	2.0	14
237	Quality of life and adherence in liver transplant recipients. <i>Minerva Gastroenterology</i> , 2018, 64, 180-186.	0.5	14
238	Long term follow-up and outcome of liver transplantation from hepatitis B surface antigen positive donors. <i>World Journal of Gastroenterology</i> , 2017, 23, 2095.	3.3	14
239	Management of bacterial infection in the liver transplant candidate. <i>World Journal of Hepatology</i> , 2018, 10, 222-230.	2.0	14
240	Protective effect of L-arginine on liver ischemia-reperfusion injury. <i>Transplantation Proceedings</i> , 1997, 29, 393-394.	0.6	13
241	Functional and morphological graft monitoring after liver transplantation. <i>Clinica Chimica Acta</i> , 2001, 310, 17-23.	1.1	13
242	Hepatitis C Infection in Patients with Chronic Kidney Disease. <i>International Journal of Artificial Organs</i> , 2008, 31, 15-33.	1.4	13
243	People's attitude toward xenotransplantation: affective reactions and the influence of the evaluation context. <i>Xenotransplantation</i> , 2009, 16, 129-134.	2.8	13
244	Alcohol Abuse and De Novo Tumors in Liver Transplantation. <i>Transplantation Proceedings</i> , 2009, 41, 1310-1312.	0.6	13
245	Head and neck and esophageal cancers after liver transplant: results from a multicenter cohort study. Italy, 1997-2010. <i>Transplant International</i> , 2015, 28, 841-848.	1.6	13
246	Physical Condition, Glycemia, Liver Function, and Quality of Life in Liver Transplant Recipients After a 12-Month Supervised Exercise Program. <i>Transplantation Proceedings</i> , 2019, 51, 2952-2957.	0.6	13
247	The psychomotor vigilance task: Role in the diagnosis of hepatic encephalopathy and relationship with driving ability. <i>Journal of Hepatology</i> , 2019, 70, 648-657.	3.7	13
248	Italian association for the study of the liver position statement on SARS-CoV2 vaccination. <i>Digestive and Liver Disease</i> , 2021, 53, 677-681.	0.9	13
249	The application of artificial intelligence in hepatology: A systematic review. <i>Digestive and Liver Disease</i> , 2022, 54, 299-308.	0.9	13
250	Evaluation of the Kinetics of Antibody Response to COVID-19 Vaccine in Solid Organ Transplant Recipients: The Prospective Multicenter ORCHESTRA Cohort. <i>Microorganisms</i> , 2022, 10, 1021.	3.6	13
251	Prospective Validation of a New Priority Allocation Model for Liver Transplant Candidates: An Interim Analysis. <i>Transplantation Proceedings</i> , 2009, 41, 1092-1095.	0.6	12
252	Antiviral therapy and fibrosis progression in patients with mild to moderate hepatitis C recurrence after liver transplantation. A randomized controlled study. <i>Digestive and Liver Disease</i> , 2012, 44, 603-609.	0.9	12

#	ARTICLE	IF	CITATIONS
253	Sorafenib use in the transplant setting. <i>Liver Transplantation</i> , 2014, 20, 1021-1028.	2.4	12
254	Successful pregnancy in Alagille Syndrome. <i>Digestive and Liver Disease</i> , 2015, 47, 86-87.	0.9	12
255	Hepatitis C virus and liver transplantation: where do we stand?. <i>Transplant International</i> , 2016, 29, 135-152.	1.6	12
256	Nonalcoholic steatohepatitis before and after liver transplant: keeping up with the times. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 173-178.	3.0	12
257	Changes in plasma circulating microvesicles in patients with HCV-related cirrhosis after treatment with direct-acting antivirals. <i>Liver International</i> , 2020, 40, 913-920.	3.9	12
258	Outcomes of Liver Transplant for Adults With Wilson's Disease. <i>Liver Transplantation</i> , 2020, 26, 507-516.	2.4	12
259	Recent Advances in the Management of Acute Variceal Hemorrhage. <i>Journal of Clinical Medicine</i> , 2021, 10, 3818.	2.4	12
260	Diagnostic and prognostic role of presepsin in patients with cirrhosis and bacterial infection. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, 775-782.	2.3	12
261	Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO). <i>Digestive and Liver Disease</i> , 2022, 54, 170-182.	0.9	12
262	Sex bias in clinical trials in gastroenterology and hepatology. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 413-414.	17.8	12
263	Isoniazid-related fulminant hepatic failure in a child: assessment of the native liver's early regeneration after auxiliary partial orthotopic liver transplantation. <i>Transplant International</i> , 2005, 17, 713-716.	1.6	11
264	Prognostic Evaluation of the Donor Risk Index Among a Prospective Cohort of Italian Patients Undergoing Liver Transplantation. <i>Transplantation Proceedings</i> , 2009, 41, 1096-1098.	0.6	11
265	Long-term outcomes of direct acting antivirals in post-transplant advanced hepatitis C virus recurrence and fibrosing cholestatic hepatitis. <i>Journal of Viral Hepatitis</i> , 2017, 24, 858-864.	2.0	11
266	The ILTS Consensus Conference on NAFLD/NASH and Liver Transplantation: Setting the Stage. <i>Transplantation</i> , 2019, 103, 19-21.	1.0	11
267	Breakthrough invasive fungal infection after liver transplantation in patients on targeted antifungal prophylaxis: A prospective multicentre study. <i>Transplant Infectious Disease</i> , 2021, 23, e13608.	1.7	11
268	Orthotopic Liver Transplantation in Non-Alcoholic Fatty Liver Disease Patients. <i>Reviews on Recent Clinical Trials</i> , 2015, 9, 210-216.	0.8	11
269	Micronuclei and broken eggs in human liver carcinogenesis. <i>Anticancer Research</i> , 2008, 28, 2507-11.	1.1	11
270	Liver transplantation and pregnancy. <i>International Journal of Gynecology and Obstetrics</i> , 1995, 50, 199-200.	2.3	10



#	ARTICLE	IF	CITATIONS
271	Vanishing bile duct syndrome. <i>British Journal of Surgery</i> , 2005, 79, 604-605.	0.3	10
272	Successful pregnancy in a liver transplant recipient treated with lamivudine for de novo hepatitis B in the graft. <i>Transplant International</i> , 2005, 17, 730-734.	1.6	10
273	Incidence of Second Primary Cancer in Transplanted Patients. <i>Transplantation</i> , 2006, 81, 982-985.	1.0	10
274	Combined Liver and Kidney Transplantation: Analysis of Padova Experience. <i>Transplantation Proceedings</i> , 2007, 39, 1933-1935.	0.6	10
275	Fibrosis Progression and the Pros and Cons of Antiviral Therapy for Hepatitis C Virus Recurrence After Liver Transplantation: A Review. <i>Transplantation Proceedings</i> , 2010, 42, 2223-2225.	0.6	10
276	Can liver transplantation provide the statistical cure?. <i>Liver Transplantation</i> , 2014, 20, 210-217.	2.4	10
277	Utility-based criteria for selecting patients with hepatocellular carcinoma for liver transplantation: A multicenter cohort study using the alpha-fetoprotein model as a survival predictor. <i>Liver Transplantation</i> , 2015, 21, 1250-1258.	2.4	10
278	De novo and recurrent malignancy. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2020, 46-47, 101680.	2.4	10
279	Cholangiocarcinoma as an Indication for Liver Transplantation in the Era of Transplant Oncology. <i>Journal of Clinical Medicine</i> , 2020, 9, 1353.	2.4	10
280	International study on the outcome of locoregional therapy for liver transplant in hepatocellular carcinoma beyond Milan criteria. <i>JHEP Reports</i> , 2021, 3, 100331.	4.9	10
281	The role of preoperative optimization of the nutritional status on the improvement of short-term outcomes after liver transplantation? A review of the literature and expert panel recommendations. <i>Clinical Transplantation</i> , 2022, 36, e14647.	1.6	10
282	Gender and Autoimmune Liver Diseases: Relevant Aspects in Clinical Practice. <i>Journal of Personalized Medicine</i> , 2022, 12, 925.	2.5	10
283	Effect of l-arginine and oligotide on liver ischemia-reperfusion injury. <i>Transplantation Proceedings</i> , 1997, 29, 2992-2993.	0.6	9
284	Comparison Between Nifedipine and Carvedilol in the Treatment of de novo Arterial Hypertension After Liver Transplantation: Preliminary Results of a Controlled Clinical Trial. <i>Transplantation Proceedings</i> , 2005, 37, 1245-1247.	0.6	9
285	Experimental hepatology applied to stem cells. <i>Digestive and Liver Disease</i> , 2008, 40, 54-61.	0.9	9
286	Post-Transplant Lymphoproliferative Disorders after Heart or Kidney Transplantation at a Single Centre: Presentation and Response to Treatment. <i>Acta Haematologica</i> , 2008, 120, 36-46.	1.4	9
287	Liver transplantation for alcoholic liver disease. <i>Clinical Liver Disease</i> , 2013, 2, 92-95.	2.1	9
288	Neuropsychiatric performance and treatment of hepatitis C with direct-acting antivirals: a prospective study. <i>BMJ Open Gastroenterology</i> , 2017, 4, e000183.	2.7	9

#	ARTICLE	IF	CITATIONS
289	Short-term outcomes of paediatric liver transplant recipients after transition to Adult Healthcare Service. <i>Liver International</i> , 2018, 38, 1316-1321.	3.9	9
290	Natural $\pm$ -IFN in HCV recurrence after liver transplantation. <i>Transplantation Proceedings</i> , 2001, 33, 1457-1458.	0.6	8
291	Warm Hepatic Ischemia in Pigs: Effects of L-Arginine and Oligotide Treatment. <i>Journal of Investigative Surgery</i> , 2001, 14, 303-312.	1.3	8
292	Bile duct stones and casts after liver transplantation: Different entities but similar prevention strategy?. <i>Liver Transplantation</i> , 2008, 14, 1400-1403.	2.4	8
293	Use of Grafts From Anti-HBc-Positive Donors in Liver Transplantation: A 5-Year, Single-Center Experience. <i>Transplantation Proceedings</i> , 2013, 45, 2707-2710.	0.6	8
294	Predictive value of induced hyperammonaemia and neuropsychiatric profiling in relation to the occurrence of post-TIPS hepatic encephalopathy. <i>Metabolic Brain Disease</i> , 2019, 34, 1803-1812.	2.9	8
295	Liver Transplantation for T2 Hepatocellular Carcinoma during the COVID-19 Pandemic: A Novel Model Balancing Individual Benefit against Healthcare Resources. <i>Cancers</i> , 2021, 13, 1416.	3.7	8
296	Coronary artery calcium on standard chest computed tomography predicts cardiovascular events after liver transplantation. <i>International Journal of Cardiology</i> , 2021, 339, 219-224.	1.7	8
297	Clinical update on the efficacy of anti-SARS-CoV-2 mRNA vaccines in patients on the waiting list for liver transplantation and in liver transplant recipients. <i>Digestive and Liver Disease</i> , 2021, 53, 1232-1234.	0.9	8
298	COVID-19 and digestive health: Implications for prevention, care and the use of COVID-19 vaccines in vulnerable patients. <i>United European Gastroenterology Journal</i> , 2021, 9, 1091-1095.	3.8	8
299	Digestive cancer screening across Europe. <i>United European Gastroenterology Journal</i> , 2022, 10, 435-437.	3.8	8
300	Myocardial perfusion scintigraphy in patients with liver cirrhosis evaluated for orthotopic liver transplantation. <i>Transplantation Proceedings</i> , 2001, 33, 1447-1448.	0.6	7
301	Frontal cerebral blood flow is impaired in patients with heart transplantation. <i>Transplant International</i> , 2002, 15, 459-462.	1.6	7
302	Treatment of genotype-1 hepatitis C recurrence after liver transplant improves survival in both sustained responders and relapsers. <i>Transplant International</i> , 2013, 26, 281-289.	1.6	7
303	Cost-effectiveness of pretransplant sofosbuvir for preventing recurrent hepatitis C virus infection after liver transplantation. <i>Transplant International</i> , 2015, 28, 1055-1065.	1.6	7
304	Hepatocellular carcinoma risk in patients with HBV-related liver disease receiving antiviral therapy. <i>Minerva Gastroenterology</i> , 2021, 67, .	0.5	7
305	Drug induced liver injury: from pathogenesis to liver transplantation. <i>Minerva Gastroenterology</i> , 2021, 67, .	0.5	7
306	Current and future perspective on targeted agents and immunotherapies in hepatocellular carcinoma. <i>Minerva Gastroenterology</i> , 2021, 67, .	0.5	7

#	ARTICLE	IF	CITATIONS
307	Sustained Complete Response after Biological Downstaging in Patients with Hepatocellular Carcinoma: XXL-Like Prioritization for Liver Transplantation or "Wait and See" Strategy?. <i>Cancers</i> , 2021, 13, 2406.	3.7	7
308	Position paper on liver and kidney diseases from the Italian Association for the Study of Liver (AISF), in collaboration with the Italian Society of Nephrology (SIN). <i>Digestive and Liver Disease</i> , 2021, 53, S49-S86.	0.9	7
309	A prospective longitudinal assessment of <i>de novo</i> metabolic syndrome after liver transplantation. <i>Clinical Transplantation</i> , 2022, 36, e14532.	1.6	7
310	Longitudinal prospective study on quality of life and psychological distress before and one year after liver transplantation. <i>Acta Gastro-Enterologica Belgica</i> , 2005, 68, 19-25.	1.0	7
311	Model for end-stage liver disease-sodium and survival benefit in liver transplantation. <i>Transplant International</i> , 2013, 26, 138-144.	1.6	6
312	Antibiotic prophylaxis for preventing postorthotopic liver transplant tuberculosis: is there a safe alternative to isoniazid?. <i>Transplant International</i> , 2017, 30, 734-736.	1.6	6
313	Outcome of critically ill cirrhotic patients admitted to the ICU: The role of ACLF. <i>Journal of Hepatology</i> , 2019, 70, 801-803.	3.7	6
314	Clinical implications of COVID-19 in patients with chronic liver disease and liver tumor. <i>Updates in Surgery</i> , 2020, 72, 237-239.	2.0	6
315	A challenging liver transplantation for decompensated alcoholic liver disease after recovery from SARS-CoV-2 infection. <i>Transplant International</i> , 2021, 34, 756-757.	1.6	6
316	R3-AFP score is a new composite tool to refine prediction of hepatocellular carcinoma recurrence after liver transplantation. <i>JHEP Reports</i> , 2022, 4, 100445.	4.9	6
317	Nash Up, Virus Down: How the Waiting List Is Changing for Liver Transplantation: A Single Center Experience from Italy. <i>Medicina (Lithuania)</i> , 2022, 58, 290.	2.0	6
318	Reply to "Peripheral versus central venous blood sampling does not influence the assessment of platelet activation in cirrhosis". <i>Platelets</i> , 2022, 33, 1104-1106.	2.3	6
319	Physiological and clinical implications of proANP(1-98) circulating levels in the perioperative phase of liver transplantation. <i>Clinica Chimica Acta</i> , 2001, 310, 39-48.	1.1	5
320	A novel approach to severe acute pancreatitis in sequential liver-kidney transplantation: the first report on the application of VAC therapy. <i>Transplant International</i> , 2011, 24, e23-e27.	1.6	5
321	Interaction between calcineurin inhibitors and IL-28B rs12979860 C>T polymorphism and response to treatment for post-transplant recurrent hepatitis C. <i>Digestive and Liver Disease</i> , 2013, 45, 927-932.	0.9	5
322	Survival Benefit of Transplantation for Recurrence of Hepatocellular Carcinoma After Liver Resection. <i>Transplantation Proceedings</i> , 2014, 46, 2287-2289.	0.6	5
323	Pancreatic melanoma metastasis diagnosed by endoscopic ultrasound-guided SharkCore biopsy. <i>Endoscopy</i> , 2016, 48, E208-E209.	1.8	5
324	The Italian compassionate use of sofosbuvir in <i>HCV</i> patients waitlisted for liver transplantation: A national real-life experience. <i>Liver International</i> , 2018, 38, 733-741.	3.9	5

#	ARTICLE	IF	CITATIONS
325	The road map toward an hepatitis C virus-free transplant population. American Journal of Transplantation, 2018, 18, 2409-2416.	4.7	5
326	Hemodynamic Evaluation of Nonselective $\beta$ -Blockers in Patients with Cirrhosis and Refractory Ascites. Gastroenterology Research and Practice, 2018, 2018, 1-7.	1.5	5
327	Outcome of a First Episode of Bacterial Infection in Candidates for Liver Transplantation. Liver Transplantation, 2019, 25, 1187-1197.	2.4	5
328	AISF position paper on HCV in immunocompromised patients. Digestive and Liver Disease, 2019, 51, 10-23.	0.9	5
329	Hepatocellular carcinoma and the risk of de novo malignancies after liver transplantation â€” a multicenter cohort study. Transplant International, 2021, 34, 743-753.	1.6	5
330	New Perspectives on Treatment of Hepatitis B Before and After Liver Transplantation. Annals of Transplantation, 2016, 21, 632-643.	0.9	5
331	Rethinking the role of non-selective beta blockers in patients with cirrhosis and portal hypertension. World Journal of Hepatology, 2016, 8, 1012.	2.0	5
332	State of the art treatment of hepatitis B virus hepatocellular carcinoma and the role of hepatitis B surface antigen postâ€”liver transplantation and resection. Liver International, 2022, 42, 288-298.	3.9	5
333	Staging the pre-procedural prophylaxis in decompensated cirrhosis. Digestive and Liver Disease, 2022, 54, 1130-1132.	0.9	5
334	Algorithm for Prioritization of Patients on the Waiting List for Liver Transplantation. Transplantation Proceedings, 2007, 39, 1855-1856.	0.6	4
335	HCV Histological Recurrence and Survival Following Liver Transplantation in Patients With and Without Hepatocellular Carcinoma. Transplantation Proceedings, 2008, 40, 1974-1975.	0.6	4
336	Cyanoacrylate injection to treat recurrent bleeding from Dieulafoy's lesion. Gastrointestinal Endoscopy, 2013, 78, 964-965.e2.	1.0	4
337	Timing for treatment of HCV recurrence after liver transplantation: the earlier the better. Transplant International, 2016, 29, 694-697.	1.6	4
338	Transplantation for acute alcoholic hepatitis. Clinical Liver Disease, 2017, 9, 141-143.	2.1	4
339	Healthâ€”related Quality of Life in Liver Transplantation: Another Step Forward. Transplant International, 2019, 32, 792-793.	1.6	4
340	HCC recurrence in HCVâ€”infected patients after liver transplantation: SILVER Study reveals benefits of sirolimus in combination with CNIs â€” a <i>postâ€”hoc</i> analysis. Transplant International, 2020, 33, 917-924.	1.6	4
341	Severe acute alcoholic hepatitis: can we offer early liver transplantation?. Minerva Gastroenterology, 2021, 67, .	0.5	4
342	Presepsin as a biomarker of inflammation and prognosis in decompensated liver disease. Journal of Hepatology, 2021, 75, 232-234.	3.7	4

#	ARTICLE	IF	CITATIONS
343	An Essential Guide for Managing Post-Liver Transplant Patients: What Primary Care Physicians Should Know. <i>American Journal of Medicine</i> , 2022, 135, 157-166.	1.5	4
344	Molecular Refinement of Clinical Staging in Hepatocellular Carcinoma Patients Evaluated for Potentially Curative Therapies. <i>PLoS ONE</i> , 2011, 6, e23093.	2.5	4
345	Severe acute alcoholic hepatitis: can we offer early liver transplantation?. <i>Minerva Gastroenterology</i> , 2021, 67, 23-25.	0.5	4
346	Metabolic activity of rat hepatocytes cultured on homologous acellular matrix and transplanted into Gunn rats. <i>International Journal of Molecular Medicine</i> , 2006, 18, 837-42.	4.0	4
347	HBV-positive and HIV-positive organs in transplantation: a clinical guide for the hepatologist. <i>Journal of Hepatology</i> , 2022, , .	3.7	4
348	Frontal cerebral blood flow is impaired in patients with heart transplantation. <i>Transplant International</i> , 2002, 15, 459-62.	1.6	4
349	<scp>Sarsâ€Cov</scp>â€2 vaccination in liver transplant recipients: The â€˜holy grailâ€™™ in a hostile environment. <i>Liver International</i> , 2022, 42, 1225-1228.	3.9	4
350	HCV infection in haemodialysed patients: A role for serum IL-10 and TGF-Î²1 in liver damage?. <i>Digestive and Liver Disease</i> , 2008, 40, 827-833.	0.9	3
351	Risk factors for portal venous thrombosis after splenectomy in patients with cirrhosis and portal hypertension ( <i>Br J Surg</i> 2010; 97: 910â€916). <i>British Journal of Surgery</i> , 2010, 97, 1452-1452.	0.3	3
352	Skills and Requirements of a Transplant Hepatologist: Board Certification of the Italian Association for the Study of the Liver (AISF). <i>Digestive and Liver Disease</i> , 2013, 45, 992-994.	0.9	3
353	Long-term maintenance of sustained virological response in liver transplant recipients treated for recurrent hepatitis C. <i>Digestive and Liver Disease</i> , 2014, 46, 440-445.	0.9	3
354	HCC criteria for liver transplantation: Controversies. <i>Liver Transplantation</i> , 2015, 21, S27-S31.	2.4	3
355	Assessment of Bleeding Risk in Patients with Cirrhosis. <i>Current Hepatology Reports</i> , 2015, 14, 9-18.	0.9	3
356	The Italian compassionate use of sofosbuvir observational cohort study for the treatment of recurrent hepatitis C: clinical and virological outcomes. <i>Transplant International</i> , 2017, 30, 1253-1265.	1.6	3
357	Switch from intravenous or intramuscular to subcutaneous hepatitis B immunoglobulin: effect on quality of life after liver transplantation. <i>Health and Quality of Life Outcomes</i> , 2020, 18, 99.	2.4	3
358	Solid Organ Transplantation During COVID-19 Pandemic: An International Web-based Survey on Resourcesâ€™™ Allocation. <i>Transplantation Direct</i> , 2021, 7, e669.	1.6	3
359	Malnourished cirrhotic patient: what should we do?. <i>Minerva Gastroenterology</i> , 2021, 67, 11-22.	0.5	3
360	Management of portal hypertension severe complications. <i>Minerva Gastroenterology</i> , 2021, 67, .	0.5	3

#	ARTICLE	IF	CITATIONS
361	Direct-acting antivirals and hepatocellular carcinoma occurrence and recurrence in hepatitis C virus-related liver cirrhosis: fact or fiction. <i>Hepatoma Research</i> , 2018, 4, 70.	1.5	3
362	Orthotopic Liver Transplantation in Alcoholic Liver Disease Patients. <i>Reviews on Recent Clinical Trials</i> , 2016, 11, 253-259.	0.8	3
363	Prevalent use of combined prophylaxis of hepatitis B after liver transplantation in Italy: results of a national survey in a large cohort. <i>Minerva Gastroenterology</i> , 2017, 64, 1-9.	0.5	3
364	Management of portal hypertension severe complications. <i>Minerva Gastroenterology</i> , 2021, 67, 26-37.	0.5	3
365	Current and future perspective on targeted agents and immunotherapies in hepatocellular carcinoma. <i>Minerva Gastroenterology</i> , 2021, 67, 4-10.	0.5	3
366	Evaluation of liver function and morphology following ischemia-reperfusion injury in pigs. <i>Transplantation Proceedings</i> , 1997, 29, 3515-3517.	0.6	2
367	Isoniazid-related fulminant hepatic failure in a child: assessment of the native liver's early regeneration after auxiliary partial orthotopic liver transplantation. <i>Transplant International</i> , 2004, 17, 713-716.	1.6	2
368	Normal cortical regional cerebral blood flow justifies the normal neuropsychological performance in patients with cholestatic liver disease. <i>Psychiatry and Clinical Neurosciences</i> , 2007, 61, 209-210.	1.8	2
369	Study of the microcirculation in hDAF transgenic rat livers xenoperfused with human blood. <i>Xenotransplantation</i> , 2009, 16, 83-90.	2.8	2
370	Antiviral treatment for HCV recurrence after liver transplantation: when, how much and for how long?. <i>Future Virology</i> , 2011, 6, 1179-1186.	1.8	2
371	108 A NOVEL MODEL OF PRIORITY ASSESSMENT FOR PATIENTS WITH AND WITHOUT HEPATOCELLULAR CARCINOMA ON A COMMON LIVER TRANSPLANT WAITING LIST: A MULTICENTRE, COHORT STUDY. <i>Journal of Hepatology</i> , 2013, 58, S48.	3.7	2
372	Can we match donors and recipients in a cost-effective way?. <i>Transplant International</i> , 2013, 26, 1061-1062.	1.6	2
373	Severe small bowel pneumatosis in adult heart transplant recipient. <i>Transplant International</i> , 2015, 28, 1002-1004.	1.6	2
374	Continuous infusion of beta-lactam antibiotics in cirrhotic patients with bloodstream infection: results from a prospective multicentre observational study. <i>Journal of Hepatology</i> , 2018, 68, S44-S45.	3.7	2
375	Fondaparinux vs low molecular weight heparin in the treatment of non malignant portal vein thrombosis in patients cirrhosis. <i>Digestive and Liver Disease</i> , 2019, 51, e42.	0.9	2
376	Ductular reaction and hepatocyte ballooning identify patients with fibrosing cholestatic hepatitis after liver transplantation. <i>Gastroenterology and Hepatology</i> , 2020, 43, 14-21.	0.5	2
377	Management of complex liver diseases. <i>Minerva Gastroenterology</i> , 2021, 67, 2-3.	0.5	2
378	<i>Geotrichum capitatum</i> Invasive Infection Early After Liver Transplant. <i>Experimental and Clinical Transplantation</i> , 2020, 18, 737-740.	0.5	2

#	ARTICLE	IF	CITATIONS
379	Human natriuretic factor in cirrhotic patients undergoing orthotopic liver transplantation. <i>Transplant International</i> , 1995, 8, 51-54.	1.6	2
380	Fulminant hepatic failure: the issue of patient selection for hazardous liver assistance. <i>Transplantation Proceedings</i> , 2000, 32, 2719-2722.	0.6	1
381	GH/GHBP changes in the perioperative course of liver transplantation: pathophysiologic and clinical implications. <i>Transplantation Proceedings</i> , 2001, 33, 1390-1392.	0.6	1
382	Histological features of donor grafts for orthotopic liver transplantation. <i>Transplantation Proceedings</i> , 2001, 33, 1177-1178.	0.6	1
383	Evaluation of graft and recipient risk factors in liver transplantation. <i>Digestive and Liver Disease Supplements</i> , 2009, 3, 108-111.	0.2	1
384	788 INTERMEDIATE STAGE HEPATOCELLULAR CARCINOMA (HCC): TO TACE OR NOT TO TACE?. <i>Journal of Hepatology</i> , 2009, 50, S288-S289.	3.7	1
385	473 NON ADHERENCE TO MEDICAL PRESCRIPTIONS IN LIVER TRANSPLANTATION: A PROSPECTIVE LONGITUDINAL STUDY. <i>Journal of Hepatology</i> , 2010, 52, S191-S192.	3.7	1
386	Infections and Organ Transplantation: New Challenges for Prevention and Treatment of Hepatitis C Virus. <i>Transplantation Proceedings</i> , 2011, 43, 2455-2456.	0.6	1
387	Cavoportal Hemitransposition Associated to Portoportal Anastomosis for Liver Transplant in Portomesenteric Thrombosis. <i>Transplantation</i> , 2013, 96, e69-e71.	1.0	1
388	Potential net health benefit of pre-transplant Sofosbuvir to prevent recurrence of HCV infection after liver transplantation: A multicenter, cohort model study. <i>Digestive and Liver Disease</i> , 2014, 46, e132-e133.	0.9	1
389	The era of the new directly acting antivirals: Has the time come for kidney transplant only in compensated cirrhosis?. <i>Transplant International</i> , 2015, 28, 620-621.	1.6	1
390	Reply to: Time to resize the role of everolimus as treatment of hepatocellular carcinoma recurrence after liver transplant. <i>Transplant International</i> , 2015, 28, 503-504.	1.6	1
391	Filling the gap between clinical trials and real life in the treatment of severe HCV recurrence after liver transplantation. <i>Transplant International</i> , 2017, 30, 239-242.	1.6	1
392	Liver transplantation: indications and outcomes. <i>Minerva Gastroenterology</i> , 2018, 64, 124-125.	0.5	1
393	P.04.7 PREVALENCE OF DE NOVO METABOLIC SYNDROME AND ITS RISK FACTORS IN A LIVER TRANSPLANTED POPULATION: A PROSPECTIVE STUDY. <i>Digestive and Liver Disease</i> , 2019, 51, e174.	0.9	1
394	SAT-115-Fondaparinux vs low molecular weight heparin in the treatment of non malignant portal vein thrombosis in patients with cirrhosis. <i>Journal of Hepatology</i> , 2019, 70, e681.	3.7	1
395	Antibiotic therapy for spontaneous bacterial peritonitis in acute-on-chronic liver failure: Handle with care. <i>Digestive and Liver Disease</i> , 2020, 52, 116-117.	0.9	1
396	Bidimensional shear wave elastography of the rectus femoris muscle in patients with cirrhosis. <i>Journal of Hepatology</i> , 2020, 73, S696.	3.7	1

#	ARTICLE	IF	CITATIONS
397	A Commentary on the Interplay Between Severity of Liver Disease and Bacterial Infection in Hospitalized Patients with Cirrhosis. <i>Digestive Diseases and Sciences</i> , 2021, 66, 640-641.	2.3	1
398	The Need for Consensus About Liver Transplantation For Patients With Neuropsychiatric Wilson's Disease. <i>Progress in Transplantation</i> , 2021, 31, 168-170.	0.7	1
399	Determinants of increased thrombotic tendency in NASH cirrhosis: not there yet!. <i>Transplant International</i> , 2021, 34, 1325-1327.	1.6	1
400	The ILTS Consensus Conference on NAFLD/NASH and liver transplantation. <i>Transplantation</i> , 2018, , 1.	1.0	1
401	Acute alcoholic hepatitis and liver transplantation: Waiting for Godot. <i>Liver International</i> , 2017, 37, 1408-1408.	3.9	1
402	Toward a novel evidence-based definition of early allograft failure in the perspective of liver retransplant. <i>Transplant International</i> , 2021, 34, 2905-2907.	1.6	1
403	Letter to the editor: Is PAI-1 a thrombotic biomarker in NASH cirrhosis?. <i>Hepatology</i> , 2022, 76, E16-E17.	7.3	1
404	Hepatitis C virus infection in end stage renal disease and after kidney transplant. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2014, 23, 340-2.	0.9	1
405	Immune Activation, Exhaustion and Senescence Profiles as Possible Predictors of Cancer in Liver Transplanted Patients. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	1
406	Role of hepatotropic viruses in the development of lymphoproliferative disorders in organ transplant recipient. <i>Gastroenterology</i> , 2000, 118, A753.	1.3	0
407	Resting energy-expenditure (REE) in cirrhotic patients: Role of plasma concentrations of leptin and tumor necrosis factor- $\alpha$ (TNF- $\alpha$ ). <i>Gastroenterology</i> , 2000, 118, A1065.	1.3	0
408	Is osteopenia a peculiar association with primary biliary cirrhosis (PBC)?. <i>Journal of Hepatology</i> , 2002, 36, 174.	3.7	0
409	Alfa-IFN (N3) plus ribavirin treatment in HCV recurrence after liver transplantation (OLT). <i>Journal of Hepatology</i> , 2002, 36, 192-193.	3.7	0
410	The role of the steatosis of the donor graft on histological features after liver transplantation (LT). <i>Gastroenterology</i> , 2003, 124, A691.	1.3	0
411	Predictive factors of HCV recurrence after liver transplantation (OLTx). <i>Gastroenterology</i> , 2003, 124, A731.	1.3	0
412	New insight in the biologic support of rat hepatocytes in primary culture. <i>Gastroenterology</i> , 2003, 124, A123.	1.3	0
413	Successful pregnancy in a liver transplant recipient treated with lamivudine for de novo hepatitis B in the graft. <i>Transplant International</i> , 2004, 17, 730-734.	1.6	0
414	Compliance to medical regimen in patients before and after liver transplantation: Are there any predictive factors?. <i>Digestive and Liver Disease</i> , 2007, 39, A38-A39.	0.9	0



#	ARTICLE	IF	CITATIONS
415	The ethical equipoise in living and deceased donor liver transplantation: Towards decision processes based on mathematical models. <i>Digestive and Liver Disease</i> , 2009, 41, A16-A17.	0.9	0
416	Facing HCV recurrence after liver transplantation: antiviral therapy response and clinical outcome. <i>Digestive and Liver Disease Supplements</i> , 2011, 5, 30-35.	0.2	0
417	523 PROTRACTED ANTIVIRAL TREATMENT BEYOND CONVENTIONAL TIME LIMITS IMPROVES SURVIVAL IN NON-RESPONDERS TO INTERFERON+RIBAVIRIN ADMINISTERED FOR HCV RECURRENCE AFTER LIVER TRANSPLANTATION. <i>Journal of Hepatology</i> , 2011, 54, S214-S215.	3.7	0
418	MELD-Na and Survival Benefit in Liver Transplantation. <i>Transplantation</i> , 2012, 94, 677.	1.0	0
419	Can the Un-Sustainable Match Be Identified in Liver Transplant Population? Evidencies from the Italian Donor-2-Recipient D-Meld Study. <i>Transplantation</i> , 2012, 94, 567.	1.0	0
420	Renal Function Deterioration Is Higher Within The First Year After Liver Transplantation: Results of The Italian Cross-Sectional, Multicenter Study (SURF).. <i>Transplantation</i> , 2014, 98, 759-760.	1.0	0
421	P973 VALUE-BASED APPROACH TO HEPATOCELLULAR CARCINOMA: OUTCOME INDICATORS TESTED IN A LARGE MULTICENTER STUDY (VBMH STUDY). <i>Journal of Hepatology</i> , 2014, 60, S399.	3.7	0
422	Effects of non-selective $\beta$ -blockers on hemodynamics and paracentesis induced circulatory dysfunction in patients with cirrhosis undergoing large volume paracentesis. <i>Digestive and Liver Disease</i> , 2014, 46, e138.	0.9	0
423	Effects of Non-Selective $\beta$ -Blockers on hemodynamic and Paracentesis Induced Circulatory Dysfunction in cirrhotics undergoing large volume paracentesis. <i>Digestive and Liver Disease</i> , 2014, 46, e59.	0.9	0
424	HCV eradication is not associated with drop-out due to HCC progression in patients awaiting liver transplantation: A monocentric experience. <i>Digestive and Liver Disease</i> , 2016, 48, e237.	0.9	0
425	Transition of pediatric liver transplanted recipients to Adult Healthcare Service: A single center cohort. <i>Digestive and Liver Disease</i> , 2016, 48, e61.	0.9	0
426	Laparoscopic ablation and salvage transplantation for patients with hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2016, 48, e24.	0.9	0
427	Circulating microparticles and risk of portal vein thrombosis in patients with liver cirrhosis and hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2016, 48, e37.	0.9	0
428	Coronary microvascular dysfunction in patients with decompensated cirrhosis: Another tool for understanding cirrhotic cardiomyopathy?. <i>Digestive and Liver Disease</i> , 2016, 48, e59.	0.9	0
429	The balance between fibrosis and regeneration in chronic liver injury: The role of gender. <i>Digestive and Liver Disease</i> , 2016, 48, e26.	0.9	0
430	Organ allocation for liver transplantation: One size does not fill all. <i>Liver Transplantation</i> , 2016, 22, 715-716.	2.4	0
431	Liver Retransplantation for Hepatic Abscess Due to Hepatic Artery Thrombosis: A Case Report. <i>Transplantation Proceedings</i> , 2017, 49, 736-739.	0.6	0
432	Prothrombotic microparticles and risk of portal vein thrombosis in patients with HCV-related liver cirrhosis who underwent DAA antiviral therapy. <i>Digestive and Liver Disease</i> , 2017, 49, e9.	0.9	0

#	ARTICLE	IF	CITATIONS
433	Outcome of liver transplant recipients after the first episode of bacterial infection. <i>Digestive and Liver Disease</i> , 2017, 49, e12.	0.9	0
434	Eradication of HCV in patients awaiting liver transplantation does not increase drop-out due to HCC progression. <i>Digestive and Liver Disease</i> , 2017, 49, e47.	0.9	0
435	Emerging players in liver fibrosis regression in a chronic murine model of hepatic injury. <i>Digestive and Liver Disease</i> , 2017, 49, e64.	0.9	0
436	Evolution of liver transplantation for alcoholic liver disease: A single center study. <i>Digestive and Liver Disease</i> , 2017, 49, e240.	0.9	0
437	Reply. <i>Liver Transplantation</i> , 2017, 23, 1630-1631.	2.4	0
438	Extending transplantation criteria for hepatocellular carcinoma. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 546-547.	8.1	0
439	Beneficial role of terlipressin in decompensated cirrhotics with spontaneous bacterial peritonitis. <i>European Journal of Gastroenterology and Hepatology</i> , 2017, 29, 366.	1.6	0
440	Gender dimorphism in fibrosis dynamics in a murine model of chronic hepatic injury. <i>Digestive and Liver Disease</i> , 2018, 50, 4-5.	0.9	0
441	The Efficacy of CMV Specific Immune Reconstitution is Highly Dependent on Donor/Recipient Serostatus and Type of Solid Organ Transplanted. <i>Transplantation</i> , 2018, 102, S334.	1.0	0
442	FRI-403-Impact on post liver transplant outcomes of response to treatment with terlipressin and albumin in patients with hepatorenal syndrome. <i>Journal of Hepatology</i> , 2019, 70, e572.	3.7	0
443	THU-071-Matrix modulation in chronic liver injury and resolution. <i>Journal of Hepatology</i> , 2019, 70, e190.	3.7	0
444	SAT-034-The psychomotor vigilance task: Role in the diagnosis of hepatic encephalopathy and relationship with driving ability. <i>Journal of Hepatology</i> , 2019, 70, e641.	3.7	0
445	The role of delta creatinine and serum albumin in predicting mortality in patients with severe alcoholic hepatitis and infection. <i>Digestive and Liver Disease</i> , 2019, 51, e29.	0.9	0
446	The role of alcoholic liver disease as risk factor for the development of de novo metabolic syndrome after liver transplantation: a prospective longitudinal study. <i>Digestive and Liver Disease</i> , 2019, 51, e51.	0.9	0
447	Development of a model based on case-mix analysis to predict 6-month patient survival after liver transplantation: a multicenter Italian study. <i>Digestive and Liver Disease</i> , 2019, 51, e11-e12.	0.9	0
448	De novo neoplasms after liver transplantation: donor gender and age influence. <i>Digestive and Liver Disease</i> , 2019, 51, e50.	0.9	0
449	Long-term liver function changes and related risk factors after direct-acting antiviral therapy in HCV-infected cirrhotic patients: results from a prospective web-based regional platform. <i>Digestive and Liver Disease</i> , 2019, 51, e16.	0.9	0
450	Outcome of critically ill patients with cirrhosis and ACLF after ICU admission. <i>Digestive and Liver Disease</i> , 2019, 51, e14.	0.9	0

#	ARTICLE	IF	CITATIONS
451	From the Editor's Desk. Journal of Hepatology, 2020, 73, 1001-1004.	3.7	0
452	From the Editor's Desk. Journal of Hepatology, 2020, 73, 475-478.	3.7	0
453	From the Editor's Desk.... Journal of Hepatology, 2020, 73, 745-748.	3.7	0
454	Reassessment of the risk of recurrence (R3) after liver transplantation for HCC: validation of the R3 v.2 score and comparison with existing models: results of a multinational analysis in 2,444 patients. Journal of Hepatology, 2020, 73, S9-S11.	3.7	0
455	De novo metabolic syndrome after liver transplantation: a prospective, longitudinal study. Journal of Hepatology, 2020, 73, S253-S254.	3.7	0
456	Long-term liver fibrosis and outcomes in HCV-infected solid organ transplant recipients after DASSs-induced viral eradication. Journal of Hepatology, 2020, 73, S609-S610.	3.7	0
457	From the Editor's Desk. Journal of Hepatology, 2020, 72, 1039-1042.	3.7	0
458	From the Editor's Desk. Journal of Hepatology, 2020, 73, 227-230.	3.7	0
459	Ductular reaction and hepatocyte ballooning identify patients with fibrosing cholestatic hepatitis after liver transplantation. Gastroenterology and Hepatology (English Edition), 2020, 43, 14-21.	0.1	0
460	Therapeutic approaches for the treatment of aging-induced stem cell dysfunction. , 2021, , 223-230.		0
461	Safe pregnancy after liver transplantation: Evidence from a multicenter Italian collaborative study. Digestive and Liver Disease, 2021, , .	0.9	0
462	Adult Liver Stem Cells. Pancreatic Islet Biology, 2014, , 319-338.	0.3	0
463	Use of Anti-HCV Positive Grafts in Liver Transplantation. , 2014, , 107-116.		0
464	Risk of renal cell cancer in people immunodepressed after solid organ transplant: Results from an Italian multicenter cohort study.. Journal of Clinical Oncology, 2014, 32, 422-422.	1.6	0
465	Oxidative Damage in Chronic and Acute Liver Disease.. , 1996, , 24-32.		0
466	EFFECTS OF CYCLOSPORINE IMMUNOSUPPRESSIVE THERAPY ON HUMAN HEMATOPOIESIS IN LIVER TRANSPLANTED PATIENTS. Transplantation, 1999, 67, S635.	1.0	0
467	Transplanting severely obese cirrhotic patients: Heavy clouds still on the horizon. United European Gastroenterology Journal, 2022, 10, 445-446.	3.8	0